RxDoctor Payments Data

Marlisa Bullock, NP

Nurse Practitioner · Charlotte, NCNPI 1134555139

Payments from drug & device makers

$3,653in general payments, 2019–2025

Across 61 payments — averaging $59.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • AbbVie$280
  • Pfizer$233
  • Boston Scientific$188
  • UCB, Inc.$174
  • SK Life Science, Inc.$151
  • plus $768 from 13 others

What the payments were for

  • Travel & lodging$89725%
  • Food & beverage$2,75675%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,653 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$17,087
Medicare patients
132
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam69$102,902
XcopriCenobamate65$101,805
EpidiolexCannabidiol (Cbd)14$52,174
Lacosamide317$43,857
ZonegranZonisamide13$35,106
TrileptalOxcarbazepine23$31,122
UbrelvyUbrogepant17$19,748
Lamotrigine ErLamotrigine52$18,987
Nurtec OdtRimegepant Sulfate13$17,930
Levetiracetam281$11,043
Clobazam48$6,379
Carbamazepine ErCarbamazepine25$5,178
Depakote ErDivalproex Sodium12$5,139
Divalproex Sodium28$3,786
Lamotrigine187$3,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$174$102,90269 claims
SK Life Science, Inc.Xcopri$151$101,80565 claims
AbbVieUbrelvy$280$19,74817 claims
PfizerNurtec Odt$233$17,93013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →